Analysing How to Show Efficacy on Top of Checkpoint Inhibitors to Show High Clinical Response Rates to Prove the Therapy is Better Than Standard of Care Treatments
- Designing combination studies to measure incremental benefits of neoantigen therapies when added to checkpoint inhibitors, focusing on recurrence-free survival and overall response rates
- Using immune monitoring and biomarker analysis to demonstrate enhanced T-cell activation, tumour infiltration, and durable anti-tumour immunity beyond standard-of care effects
- Highlighting trial strategies, including patient stratification and adaptive endpoints, to clearly differentiate the added clinical value of neoantigen therapies over existing treatments